Navigation Links
Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
Date:12/13/2011

sclosed sales milestones, and tiered, double-digit royalties on global revenues.  Ambit also has an option to co-promote products in the U.S. where Astellas and Ambit share equally all profits and losses generated from U.S. sales.

About Ambit Biosciences

Ambit Biosciences is a privately held biopharmaceutical company engaged in the development of a robust pipeline of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease and other indications.  Ambit's lead compound, quizartinib (AC220), is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML.  Ambit is developing quizartinib in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications.  In addition to quizartinib, Ambit's clinical pipeline includes AC430, an oral JAK2 inhibitor, and AC480, a pan-HER inhibitor. Ambit also has a preclinical candidate, CEP-32496, and a BRAF inhibitor licensed to Cephalon.  For more information, visit www.ambitbio.com.

About Astellas

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through provision of innovative and reliable pharmaceuticals. Astellas has approximately 16,800 employees worldwide. The organization is committed to becoming a global category leader in Urology, Immunology including Transplantation and Infectious Diseases, Oncology, Neuroscience, and DM complications and Metabolic Diseases. For more information on Astellas Pharma Inc., please visit our website at www.astellas.com/en.

Contacts:
Ambit Biosciences:
Alan Fuhrman
Chie
'/>"/>

SOURCE Ambit Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
2. Ambit Biosciences Announces Transition in Company Leadership
3. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
4. Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
5. Astellas Awards Educational Scholarships to Six Transplant Recipients Who Embody the Spirit of Giving Back
6. Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
7. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
8. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
9. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
10. CV Therapeutics Statement on Unsolicited Proposal From Astellas
11. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... DUBLIN , Aug. 19, 2014 Research and ... Culture Supplies - Global Strategic Business Report" report to their ... Cell and Tissue Culture Supplies in US$ Thousands by the following ... separate comprehensive analytics for the US, Canada , ... Asia-Pacific , and Latin America . ...
(Date:8/19/2014)... , Aug. 19, 2014 Research and ... Fuel Cells (SOFCs) - Global Strategic Business Report" report ... worldwide markets for Solid Oxide Fuel Cells (SOFCs) in US$ ... Canada , Europe , ... estimates and forecasts are provided for the period 2012 through ...
(Date:8/19/2014)... 2014 Research and Markets ... "Spectroscopy Equipment and Accessories - Global ... offering. This report analyzes ... Accessories in US$ Thousands by the following ... Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) Spectrometers, ...
(Date:8/19/2014)... 19, 2014   Synthetic Biologics, Inc. ... anti-infective biologic and drug programs targeting specific pathogens ... that its novel C. difficile development ... Interscience Conference on Antimicrobial Agents and Chemotherapy ... Synthetic Biologics, Senior Vice ...
Breaking Biology Technology:Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4
... Almost by accident, I find myself on what must surely ... the past few months, I have tried the best designs ... I've tried has great strengths and a few tradeoffs, usually ... along comes a Bluetooth wireless headset from a newcomer to ...
... major advantages , ,MADISON, Wis. Wisconsins biotechnology ... feature appearing in the June issue of Modern Drug ... clusters in Madison and Milwaukee, and attributes the growth ... and universities, the Wisconsin Alumni Research Foundation , ...
... lack of funding cited as problems , ,MADISON ... and keep customers happy isnt exactly a revolutionary practice. ... lack funding, even the smallest technological alteration can be ... Matt Miszewski and other speakers described this paradox and ...
Cached Biology Technology:The quest for the perfect headset 2The quest for the perfect headset 3Wisconsin biotech sector featured in scientific magazine 2Wisconsin biotech sector featured in scientific magazine 3State CIO discusses IT and government 2
(Date:8/20/2014)... Aug. 20, 2014 /CNW/ -  Issue ... can quickly become life threatening for some children.    ... 1.2 million Canadians have food allergies and this number may ... of children are estimated to have food allergies.  ... skin irritations and hives to breathing difficulties and loss of ...
(Date:8/20/2014)... Area Lyme Foundation, which aims to make Lyme disease ... research published in an upcoming issue of the Elsevier ... The findings show that ticks that carry Lyme ... making the threat of Lyme disease year-round. The research ... Health (CDPH) Vector-borne Disease Section and University of California, ...
(Date:8/20/2014)... sunscreen and seawater signals a relaxing trip to the ... beach vacation comes with an environmental hitch. When certain ... they can become toxic to some of the ocean,s ... other marine animals. Their study appears in the ACS ... Tovar-Sanchez and David Snchez-Quiles point out that other than ...
Breaking Biology News(10 mins):Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3
... Wisconsin research team, led by John W. Lough, Ph.D., professor ... stem cells (ES cells) in animals can be cultivated to ... to replace tissue damaged as a result of a heart ... or diseased cells in adult tissues has caused extraordinary interest ...
... Durham, N.C. ?A new understanding of the causes for symptoms ... 600 African-Americans, has resulted from a study by researchers at ... Their findings may lead to a new, more direct method ... that an inability of red blood cells to relax blood ...
... each year worldwide, causing one million deaths. Around 90% ... children. One of the greatest challenges facing Africa in ... chloroquine (CQ), the cheapest and most widely used antimalarial, ... the first-developed and least expensive alternative to CQ, is ...
Cached Biology News:Stem Cell Research Shows Potential for Replacing Tissue Damaged in Heart Attacks 2Discovery Promises Simpler Therapy for Sickle Cell Disease 2Discovery Promises Simpler Therapy for Sickle Cell Disease 3Reducing malarial transmission in Africa 2
RABBIT ANTI QUINOLINIC ACID...
RAT ANTI MOUSE METALLOPHILIC MACROPHAGES...
... All MagCellect Ferrofluid products perform ... with R&D Systems MagCellect Magnet. ... this neodymium iron boron permanent ... x 75 mm test tubes ...
Request Info...
Biology Products: